Loading…
for educational and safety purposes
class, effects, and the receptor fingerprint, side by side; add up to four, then source the whole stack
Popular head-to-heads →Choline transporter CHT1 (HACU)enhances
Cholinergic signalingstrengthens
AMPA receptorsmild potentiation
High-affinity choline transporter CHT1 / CHT (gene SLC5A7)Proposed positive modulator. Reported to raise the Vmax of high-affinity choline uptake about 1.6-fold and the Bmax of [3H]-hemicholinium-3 binding about 1.7-fold, interpreted as driving more transporter to the synaptic membrane rather than changing transporter affinity. Critically, the effect is reported ONLY in cholinergically lesioned tissue and is absent in normal tissue.
Acetylcholine synthesis and release (downstream consequence, not a receptor)Increase, again restricted to lesioned tissue. Reversed the AF64A-induced fall in potassium-evoked ACh release from hippocampal synaptosomes and slices, and restored basal hippocampal ACh by in vivo microdialysis. In mice, only chronic dosing restored hippocampal ACh; acute dosing did nothing.
Acetylcholinesterase (AChE)No inhibition. This is affirmative negative evidence from a direct assay, and it distinguishes coluracetam from donepezil, tacrine and the rest of the cholinesterase-inhibitor class.
Muscarinic acetylcholine receptorsNo binding. Neither [3H]-quinuclidinyl benzilate (general muscarinic) nor [3H]-pirenzepine (M1-preferring) binding was affected, so the compound is not a muscarinic ligand.
BDNF / NGFupregulates
AMPA receptoragonist
Antioxidant systemsenhances
Cholinergic tonesupports
checking Coluracetam and Noopept: no adverse interactions were flagged (1 compatible pair); the pairs read as compatible at the class level.
Coluracetam and racetams both act on the cholinergic system; no adverse class-level interaction flagged.
General educational info, not medical advice.
The vendors that carry the most of your 2 picks; fewer vendors, fewer codes, less shipping.